Toggle light / dark theme

Faecal swaps could help stop heart transplants from being rejected

Not sure about this, microbiome is known to be quite stable and to revert back to some kind of base line…even after faecal swaps… Curious what that could mean over time.


By Clare Wilson

The key to organ transplants might lie in an unexpected place – the gut. Giving mice a faecal transplant made them more tolerant of a subsequent heart transplant.

The explanation could be that bacteria in the bowel help regulate the immune system and stop it from launching an attack against the unfamiliar transplanted tissue. Finding the mechanism could lead to new medicines to stop organ rejection, says Jonathan Bromberg at the University of Maryland. “It’s a way to turn down the volume knob on the immune system.”

5 Sci-Fi Books Biotech Geeks Should Read Right Now

From space colonization to resurrection of dinosaurs to machine intelligence, the most awe-inspiring visions of humanity’s future are typically born from science fiction.

But among an abundance of time travel, superheroes, space adventures, and so forth, biotech remains underrepresented in the genre.

This selection highlights some outstanding works (new and not so new) to fill the sci-fi gap for biotech aficionados.

Replacing fertilizer with plant probiotics could slash greenhouse gases

Pivot Bio just got a $70 million infusion from Bill Gates’s energy fund and other investors to launch its commercial product next year.

The science: The biotechnology company, based in Berkeley, California, is creating probiotics for plants. The firm’s researchers have identified microbes with a dormant ability to produce nitrogen, a crucial nutrient in synthetic fertilizer, and engineered them to reawaken and enhance it. For its initial product, Pivot Bio has created a liquid treatment for corn crops that can be applied when the seeds are planted.

The sell: In early field tests, patches treated with the microbes produce comparable yields to those relying on synthetic fertilizers. Pivot Bio’s pitch to farmers is that the product reduces work and complexity, because a single application takes less time than spraying multiple rounds of fertilizer.

Forcing Cancer to Put up a Broken Shield

A new discovery might make immunotherapy applicable to more patients.


Led by Dr. Alicja Copik, scientists at the University of Central Florida College of Medicine have discovered that it might be possible to make cancer immunotherapy work for a larger portion of patients by employing PM21-activated natural killer (PM21-NK) cells [1].

Study abstract

Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors. Hence, strategies that increase PD-L1 expression and tumor infiltration should make more patients eligible for PD-1/PD-L1 blockade therapy, thus improving overall outcomes. PD-L1 expression on tumors is induced by IFNγ, a cytokine secreted by NK cells. Therefore, we tested if PM21-particle expanded NK cells (PM21-NK cells) induced expression of PD-L1 on tumors and if anti-PD-L1 treatment enhanced NK cell anti-tumor efficacy in an ovarian cancer model. Studies here showed that PM21-NK cells secrete high amounts of IFNγ and that adoptively transferred PM21-NK cells induce PD-L1 expression on SKOV-3 cells in vivo. The induction of PD-L1 expression on SKOV-3 cells coincided with the presence of regulatory T cells (Tregs) in the abdominal cavity and within tumors.

Translating Aging Research – Ending Age-Related Diseases 2018 Panel

Today, we have another video from our Ending Age-Related Diseases 2018 conference, which was held earlier this year at the Cooper Union in New York City. The conference was designed to bring the worlds of research and investment together in one place and explore the progress and challenges that the industry faces in developing and funding therapies to end age-related disease.

This was the second panel during the conference and featured Dr. Aubrey de Grey of the SENS Research Foundation, Keith Comito of Lifespan.io, Dr. James Peyer of Apollo Ventures, Dr. Mark Hammond of Deep Science Ventures, Joe Betts Lacroix of Y Combinator and Vium, Dr. Oliver Medvedik of Lifespan.io and The Cooper Union, and Ramphis Castro of ScienceVest.

/* */